(Q45992466)

18 December 2017

title

Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study. (English)

1 reference

18 December 2017

recurrent endometrial cancer

main subject

1 reference

5

P Braly

0 references

author name string

D S McMeekin

1

1 reference

18 December 2017

A Lisyanskaya

2

1 reference

18 December 2017

M Crispens

3

1 reference

18 December 2017

A M Oza

4

1 reference

18 December 2017

D Doering

6

1 reference

18 December 2017

E Bayever

7

1 reference

18 December 2017

B Michiels

8

1 reference

18 December 2017

M Markman

9

1 reference

18 December 2017

language of work or name

English

0 references

publication date

23 May 2009

1 reference

18 December 2017

published in

Gynecologic Oncology

1 reference

18 December 2017

volume

114

1 reference

18 December 2017

issue

2

1 reference

18 December 2017

page(s)

288-292

1 reference

18 December 2017

Randomized Phase III Trial of Standard Timed Doxorubicin Plus Cisplatin Versus Circadian Timed Doxorubicin Plus Cisplatin in Stage III and IV or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Optimal two-stage designs for phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

inferred from DOI database lookup

7 January 2021

based on heuristic

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.034

10.1016/J.YGYNO.2009.04.034

7 January 2021

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017